1Arbuckle MR,McClain MT,Rubertone MV,et al.Development of autoantibodies before the clinical onset of systemic lupus erythematosus[J].N Engl J Med,2003,349 (16):1 526-1 533.
2Liu CC,Navratil JS,Sabatine JM,et al.Apoptosis,complement and systemic lupus erythematosus:a mechanistic view[J].Curr Dir Autoimmun,2004,7:49-86.
3Creagh EM,Conroy H,Martin SJ.Caspase.activation pathways in apoptosis and immunity[J].Immunol Rev,2003,193:10-21.
4Tan EM,Cohen AS,Fries JF,et al.The 1982 revised criteria for the classification of systemic lupus erythematosus[J].Arthritis Rheum,1982,25(11):1 271-1 277.
5Bombardier C,Gladman DD,Urowitz MB,et al.Derivation of the SLEDAI.A disease activity index for lupus patients.The Committee on Prognosis Studies in SLE[J].Arthritis Rheum,1992,35(6):630-640.
6Mevorach D.Systemic lupus erythematosus and apoptosis:a question of balance[J].Clin Rev Allergy Immunol,2003,25(1):49-60.
7Krueger A,Fas SC,Baumann S,et al.The role of CD95 in the regulation of peripheral T.cell apoptosis[J].Immunol Rev,2003,193:58-69.
8Perl A,Gergely P Jr,Banki K.Mitochondrial dysfunction in T cells of patients with systemic lupus erythematosus[J].Int Rev Immunol,2004,23(3/4):293-313.
9Suchkov SV.Mechanisms underlying cytotoxicity of anti.DNA antibodies[J].Bull Exp Biol Med,2001,131(5):475-478.
10Bonomini M.Dottori S,Amoroso L,et al.Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia[J].J Thromb Haemost,2004,2(8):1 275-1 281.
